Utilization of Paragonix SherpaPak for human donor heart preservation

2021 ◽  
Keyword(s):  
Gold Standard ◽  
Standard Treatment ◽  
Donor Heart ◽  
Preservation Solution ◽  
Human Donor ◽  
Heart Preservation ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Transplant Procedure ◽  
Continuous Temperature

A heart transplant is the gold standard treatment for end stage heart failure. Preservation of the donor heart during its transfer from the hospital of the donor to that of the recipient has a significant impact on the outcome of the transplant procedure. Icebox storage is a conventional method utilized for this purpose that may not provide uniform cooling of the donor heart and does not allow monitoring of the temperature of the donor heart during preservation. The Paragonix SherpaPak Cardiac Transport System offers uniform cooling by suspending the donor heart in a preservation solution and provides continuous temperature monitoring.

scholarly journals Zebrafish as a New Tool in Heart Preservation Research

2021 ◽  
Vol 8 (4) ◽  
pp. 39
Author(s):  
Luciana Da Silveira Cavalcante ◽  
Shannon N. Tessier
Keyword(s):  
New Technologies ◽  
Ex Vivo ◽  
Machine Perfusion ◽  
Life Saving ◽  
First Choice ◽  
Heart Preservation ◽  
End Stage Heart Failure ◽  
Ischemia Tolerance ◽  
The 1960S ◽  
End Stage

Heart transplantation became a reality at the end of the 1960s as a life-saving option for patients with end-stage heart failure. Static cold storage (SCS) at 4–6 °C has remained the standard for heart preservation for decades. However, SCS only allows for short-term storage that precludes optimal matching programs, requires emergency surgeries, and results in the unnecessary discard of organs. Among the alternatives seeking to extend ex vivo lifespan and mitigate the shortage of organs are sub-zero or machine perfusion modalities. Sub-zero approaches aim to prolong cold ischemia tolerance by deepening metabolic stasis, while machine perfusion aims to support metabolism through the continuous delivery of oxygen and nutrients. Each of these approaches hold promise; however, complex barriers must be overcome before their potential can be fully realized. We suggest that one barrier facing all experimental efforts to extend ex vivo lifespan are limited research tools. Mammalian models are usually the first choice due to translational aspects, yet experimentation can be restricted by expertise, time, and resources. Instead, there are instances when smaller vertebrate models, like the zebrafish, could fill critical experimental gaps in the field. Taken together, this review provides a summary of the current gold standard for heart preservation as well as new technologies in ex vivo lifespan extension. Furthermore, we describe how existing tools in zebrafish research, including isolated organ, cell specific and functional assays, as well as molecular tools, could complement and elevate heart preservation research.

University of Wisconsin solution for human donor heart preservation: Initial clinical experience

1991 ◽  
Vol 52 (6) ◽  
pp. 1213-1216 ◽  
Author(s):  
Valluvan Jeevanandam ◽  
Mark L. Barr ◽  
Joseph S. Auteri ◽  
Juan A. Sanchez ◽  
Gary Y. Ott ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Donor Heart ◽  
Human Donor ◽  
University Of Wisconsin Solution ◽  
University Of Wisconsin ◽  
Heart Preservation ◽  
Wisconsin Solution ◽  
Initial Clinical Experience

scholarly journals Anesthesia for Liver Transplantation

2021 ◽  
Author(s):  
Zeynep Ersoy ◽  
Nedim Çekmen ◽  
Adnan Torgay
Keyword(s):  
Liver Transplantation ◽  
Gold Standard ◽  
Multidisciplinary Approach ◽  
Standard Treatment ◽  
Perioperative Period ◽  
Hemodynamic Instability ◽  
Anesthesia Management ◽  
End Stage Liver Disease ◽  
End Stage ◽  
Disease Understanding

Orthotopic liver transplantation (OLT) is the gold standard treatment for patients with end-stage liver disease. Understanding of the multisystem physiology of end stage liver desease (ESLD) is fundamental to the management of transplant recipient. Since OLT is a very dynamic process, a multidisciplinary approach and optimization is essential in the perioperative period. During the management anesthesiologists should focus on significant hemodynamic instability, physiology, metabolic disturbance and coagulopathy of those patients. The aim of this review was to summarize peroperative and anesthesia management in line with the guidelines.

University of Wisconsin versus St. Thomas' Hospital solution for human donor heart preservation

1993 ◽  
Vol 55 (5) ◽  
pp. 1131-1137 ◽  
Author(s):  
Stefanos Demertzis ◽  
Jens Wippermann ◽  
Jutta Schaper ◽  
Thorsten Wahlers ◽  
Hans-Joachim Schäfers ◽  
...  
Keyword(s):  
Donor Heart ◽  
Human Donor ◽  
University Of Wisconsin ◽  
Heart Preservation

scholarly journals Postoperative pericardial effusion: peculiarities of the development and course

2021 ◽  
Vol 23 (1) ◽  
pp. 131-139
Author(s):  
K. S. Kiriakov ◽  
V. M. Zakharevich ◽  
T. A. Khalilulin ◽  
N. Y. Zakharevich ◽  
N. N. Abramova ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Cardiac Surgery ◽  
Chronic Heart Failure ◽  
Pericardial Effusion ◽  
Heart Transplantation ◽  
Gold Standard ◽  
Standard Treatment ◽  
Life Threatening ◽  
End Stage

Heart transplantation continues to be the gold standard treatment for end-stage chronic heart failure. As with any cardiac surgery, heart transplantation is associated with postoperative complications. One of the most common complications is postoperative pericardial effusion. Heart recipients have a greater risk of developing pericardial effusion than patients after cardiac surgery on their own heart, due to surgical and immunological features. Severe pericardial effusions negatively affect the postoperative period and may be the cause of life-threatening conditions. Identification of risk factors, prevention, early diagnosis and treatment of this disease can significantly reduce the risks of adverse events in this group of patients. The purpose of this literature review is to analyze the development and course of pericardial effusion in heart recipients in world practice.

scholarly journals New Insights in the Diagnosis and Treatment of Heart Failure

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Giulio Agnetti ◽  
Massimo F. Piepoli ◽  
Giuseppe Siniscalchi ◽  
Francesco Nicolini
Keyword(s):  
Heart Failure ◽  
Gold Standard ◽  
Diagnosis And Treatment ◽  
Coronary Syndrome ◽  
Developing Heart ◽  
Standard Medical Therapy ◽  
The Us ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Surgical Treatments

Cardiovascular disease is the leading cause of mortality in the US and in westernized countries with ischemic heart disease accounting for the majority of these deaths. Paradoxically, the improvements in the medical and surgical treatments of acute coronary syndrome are leading to an increasing number of “survivors” who are then developing heart failure. Despite considerable advances in its management, the gold standard for the treatment of end-stage heart failure patients remains heart transplantation. Nevertheless, this procedure can be offered only to a small percentage of patients who could benefit from a new heart due to the limited availability of donor organs. The aim of this review is to evaluate the safety and efficacy of innovative approaches in the diagnosis and treatment of patients refractory to standard medical therapy and excluded from cardiac transplantation lists.

scholarly journals University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation

1992 ◽  
Vol 103 (2) ◽  
pp. 194-199 ◽  
Author(s):  
Valluvan Jeevanandam ◽  
Mark L. Barr ◽  
Joseph S. Auteri ◽  
Juan A. Sanchez ◽  
Johnathan Fong ◽  
...  
Keyword(s):  
Donor Heart ◽  
Human Donor ◽  
Solution Versus ◽  
University Of Wisconsin Solution ◽  
University Of Wisconsin ◽  
Heart Preservation ◽  
Wisconsin Solution

scholarly journals iPS-abgeleitete Kardiomyozyten als therapeutische Hoffnungsträger

BIOspektrum ◽  
2021 ◽  
Vol 27 (4) ◽  
pp. 362-364
Author(s):  
Nina Grill ◽  
Lisa Fellner ◽  
Marcel Tisch ◽  
Frank Edenhofer
Keyword(s):  
Gold Standard ◽  
Human Heart ◽  
Scar Tissue ◽  
Therapeutic Interventions ◽  
Limited Capacity ◽  
Donor Heart ◽  
Realistic Option ◽  
Fibrotic Scar ◽  
End Stage ◽  
And Function

AbstractAfter ischemic injury in adolescence, the human heart has only limited capacity to regenerate. The loss of cardiomyocytes is typically replaced by fibrotic scar tissue. The resulting scars reduce myocardial contractility and function. To date, the gold standard for end-stage heart disease remains a heart transplant, which is not a realistic option due to donor heart shortage. The regenerative potential of reprogrammed stem cells has the potential for a long-expected breakthrough in development of efficient therapeutic interventions.

Donors after circulatory death heart trial

2021 ◽  
Vol 17 (1) ◽  
pp. 11-17
Author(s):  
Yasuhiro Shudo ◽  
Rhodalene Benjamin-Addy ◽  
Tiffany K Koyano ◽  
William Hiesinger ◽  
John W MacArthur ◽  
...  
Keyword(s):  
Heart Failure ◽  
Gold Standard ◽  
Orthotopic Heart Transplantation ◽  
Donation After Circulatory Death ◽  
Clinical Trial Registration ◽  
Life Saving ◽  
End Stage Heart Failure ◽  
Standard Life ◽  
End Stage ◽  
Circulatory Death

Orthotopic heart transplantation is the gold standard treatment for end-stage heart failure. However, the persistent shortage of available donor organs has resulted in an ever-increasing waitlist and longer waiting periods for transplantation. On the contrary, increasing the number of heart transplants by preserving extended criteria donors and donation after circulatory death hearts with the Organ Care System™ (OCS) Heart System has the potential to provide the gold standard, life-saving treatment to patients with end-stage heart failure. The objective of the Donation After Circulatory Death Heart Trial is to evaluate the effectiveness of the OCS Heart System to preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation, which can potentially provide patients with end-stage heart failure with the life-saving treatment. Clinical Trial Registration: NCT03831048 ( ClinicalTrials.gov )

Sign in / Sign up

Export Citation Format

Share Document